Latest News and Press Releases

Freiburg, den 7. Mai 2025 Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes Arzneimittel...

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary...

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.

Blair, Nebraska, April 10, 2024 (GLOBE NEWSWIRE) -- Great Plains Communications (GPC), the Midwestern digital infrastructure provider with a growing, privately owned 18,000+ mile fiber network...

Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.

NEWCASTLE UPON TYNE, United Kingdom, March 05, 2024 (GLOBE NEWSWIRE) -- PSC Consulting is pleased to announce the appointment of James Drummond as Managing Director of its European operations. The...

GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...

BELFIELD, N.D., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Energy Group, Inc., the leading innovator in the petroleum refining industry, announced today that the North Dakota Supreme Court ruled in...

BELFIELD, N.D., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Meridian Energy Group, Inc., the leading developer of innovative and environmentally-compliant oil refining facilities, announced today that a...